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Differential contributions of 
peripheral and central mechanisms 
to pain in a rodent model of 
osteoarthritis
Adrian R. Haywood, Gareth J. Hathway  & Victoria Chapman
The mechanisms underlying the transition from acute nociceptive pain to centrally maintained chronic 
pain are not clear. We have studied the contributions of the peripheral and central nervous systems 
during the development of osteoarthritis (OA) pain. Male Sprague-Dawley rats received unilateral 
intra-articular injections of monosodium iodoacetate (MIA 1 mg) or saline, and weight-bearing (WB) 
asymmetry and distal allodynia measured. Subgroups of rats received intra-articular injections of, 
QX-314 (membrane impermeable local anaesthetic) + capsaicin, QX-314, capsaicin or vehicle on 
days 7, 14 or 28 post-MIA and WB and PWT remeasured. On days 7&14 post-MIA, but not day 28, 
QX-314 + capsaicin signficantly attenuated changes in WB induced by MIA, illustrating a crucial role 
for TRPV1 expressing nociceptors in early OA pain. The role of top-down control of spinal excitability 
was investigated. The mu-opioid receptor agonist DAMGO was microinjected into the rostroventral 
medulla, to activate endogenous pain modulatory systems, in MIA and control rats and reflex 
excitability measured using electromyography. DAMGO (3 ng) had a significantly larger inhibitory 
effect in MIA treated rats than in controls. These data show distinct temporal contribtuions of TRPV1 
expressing nociceptors and opioidergic pain control systems at later timepoints.
Osteoarthritis (OA) is a common form of degenerative joint disease and a major cause of joint pain worldwide1. 
Structural changes within the joint are well characterised, however the mechanisms of OA pain are less clearly 
defined2,3. Patients with OA pain have symptoms consistent with hyperalgesia including altered lower limb 
reflexes4, lowered mechanical pain thresholds at sites distal to the diseased joint and facilitated temporal sum-
mation5. Around 30% of patients exhibit features consistent with central sensitisation mechanisms6. Synovitis 
is significantly associated with OA pain7,8 and increased levels of pro-inflammatory mediators in synovial fluid 
sensitise nociceptors9. These nociceptors are primary afferent sensory neurons which innervate multiple compo-
nents of the joint and detect changes in the local environment, as well as being potential sources of nociceptive 
factors themselves. Intra-articular injection of the local anaesthetic lidocaine significantly reduced pain scores in 
OA patients10, supporting the importance of a peripheral drive to OA pain, however whether all sensory fibres, or 
just subsets, are sensitised in OA is unknown.
As well as primary afferent sensory input to the spinal cord and higher brain centres, supraspinal net-
works powerfully control spinal excitability and hyperalgesia. Preclinical studies support the contribution of 
supra-spinal mechanisms to the maintenance of chronic pain11 including in models of OA pain12. Descending 
control mechanisms arise from multiple supra-spinal sites, changes in neuronal activity in the rostral ventrome-
dial medulla (RVM)11 has a fundamental role in the modulating spinal dorsal horn excitability13. Descending 
modulation is altered in OA patients14,15, however identifying the underlying structures and mechanisms respon-
sible and the timecourse over which central mechanisms become clinically significant necessitates the use of 
translationally relevant animal models.
Although a range of OA pain models have been developed, given the complex nature of OA in humans there 
is no single ‘gold standard’ model which can replicate all aspects of human OA16. Recent reviews confirm the 
value of both surgical and chemical models17. The mono-sodium iodoacetate (MIA) model of OA has been used 
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extensively to study structural features of OA18 and pain behaviour19,20 in the rodent. Intra-articuar injection of 
MIA results in extensive cartilage degradation and subchondral bone changes at later timepoints19, which is dose 
and time dependent. Studies using an intermediate dose report structural changes to the joint commensurate 
with that seen in human OA joints21. Concomitant MIA-induced pain behaviour (weight bearing asymmetry 
(WB) and lowered paw withdrawal thresholds (PWT)) models aspects of activity-related pain and altered distal 
pain pressure thresholds in OA patients19,22. This model is also associated with hallmarks of of spinal20,23 and 
supraspinal24 sensitization.
We hypothesised that there are differential contributions of the peripheral and central nervous system to MIA 
induced OA pain over time, which are relevant to the development of novel treatment approaches.
Results
Joint pathology was assessed post-mortem. Macroscopic scoring in six compartments of the knee in MIA and 
saline injected rats showed significantly higher scores in the treated group than in the controls (Supplemental 
Fig. 1). Further macroscopic scoring increased significantly over time.
Targeted inactivation of joint nociceptors attenuates pain evoked by intra-articular injection 
of NGF. The first study confirmed whether targetted inactivation of joint nociceptors reversed pain behaviour 
evoked by a well studied sensitising agent. NGF is a key mediator of OA pain and is able to sensitise nocieptors 
in the joint. The ability of the membrane impermeable local anaesthetic QX314 with capsaicin to block acute 
joint pain responses following intra-articular administration of NGF was determined. Intra-articular injection 
of NGF (10 ug) evoked significant WB asymmetry (p < 0.0001;Fig. 1A) and a reduction in PWTs (p < 0.001; 
Fig. 1B) 2 hours post injection of NGF. Concomitant intra-articular injection of QX-314 (1 mg/50 ul) with capsa-
icin (1 ug/ul) significantly attenuated NGF-induced WB asymmetry (p = 0.0004; Fig. 1A), compared to all other 
intra-articular interventions. Intra-articular injection of QX-314 (1 mg/50 ul) with capsaicin (1 ug per ul) did not 
however alter NGF-induced changes in PWT (p > 0.05; Fig. 1B). Intra-articular injection of QX-314 (1 mg/50 ul), 
lidocaine (1 mg/50 ul), capsaicin (1 ug/ul; Sigma) or vehicle (5% EtOH, 5% tween-20, 90% saline 0.9%) did not 
alter NGF-induced WB asymmetry or PWTs. These data show that in an established model of joint hyperalgesia, 
targeted inactivation of TRPV1 expressing C-fibres are able to reverse WB asymmetry, but not lowered PWTs.
MIA-induced weight bearing asymmetry is dependent upon TRPV1 positive joint nociceptor 
activation at early time points. Next we studied the contributions of nociceptors innervating the joint 
versus central pain facilitating pathways to hyperalgesia in a model of joint damage over time. Intra-articular 
injection of MIA (1 mg/50 ul) resulted in significant WB asymmetry at day 7 (p < 0.0001; Fig. 2A), day 14 
(p < 0.0001; Fig. 2C) and day 28 (p < 0.0001; Fig. 2E) compared to baseline values. In our NGF study lidocaine 
failed to reverse changes in PWT or WB, whereas targeted inactivation of TRPV1 expressing nociceptors did. We 
therefore decided to investigate the contribution of these TRPV1 positive sensory nerve fibres in MIA induced 
pain behaviours.
In rats at 7 days following intra-articular injection of MIA, intra-articular injection of QX-314 (1 mg/50 ul) 
with capsaicin (1 ug/μl) significantly reduced WB asymmetry (Fig. 2B) compared to baseline. Intra-articular cap-
saicin significantly potentiated WB asymmetry 30 and 60 mins post application, compared to baseline (Fig. 2B). 
None of the other intra-articular manipulations had significant effects on WB in MIA treated rats at this time 
point compared to baseline. Comparisons of the mean response to these intra-articular manipulations between 
groups over the entire 180 min observation period demonstrated significant differences between QX-314 + capsa-
icin treated rats with those treated with just capsaicin (p < 0.001), or vehicle (p < 0.05; Table 1).
The same intra-articular drug applications were made in a separate cohort of rats 14 days after MIA injec-
tion. At this timepoint only QX-314 (1 mg/50 ul) with capsaicin (1 ug/μl) significantly reduced WB asymme-
try compared to baseline, none of the other treatments altered WB asymmetry (Fig. 2D). QX314 and capsaicin 
co-administration had a significantly different effect to all other drug treatment groups at day 14 post-MIA over 
the entire 180 min observation period (see Table 1).
Finally at Day 28 post-MIA the same pharmacological treatments were also applied intra-articularly in 
another cohort of rats. At this timepoint administration of QX-314 (1 mg/50 ul) with capsaicin (1 ug/μl) had no 
effect upon WB asymmetry compared to baseline values. Capsaicin however was able to increase WB asymmetry 
at this timepoint.
Intra-articular injection of MIA (1 mg/50 ul) resulted in significant PWT asymmetry at day 7 (p < 0.0001; 
Fig. 3A), day 14 (p < 0.0001; Fig. 3C) and day 28 (p < 0.0001; Fig. 3E). Unlike WB, intra-articular administration 
of QX-314 with capsaicin, QX314, capsaicin or vehicle at each of these timepoints had no effect upon PWT when 
compared to each other or their respective baseline (pre-local anaesthetic) values (Fig. 3B,D–F).
MIA-induced central sensitization: facilitation of EMG responses. To advance understanding of 
the contribution of central mechanisms to MIA-induced pain over time, EMG responses were recorded at dif-
ferent timepoints and the effects of altering the output of the RVM on these responses were quantified in sepa-
rate groups of rats. Our EMG approach permits discrete pharmacological manipulation of brainstem structures, 
whilst preserving spinal reflexes and has been used to investigate opioidergic signalling in descending pain con-
trol systems previously25. It also overcomes animal welfare concerns associated with supraspinal microinjections 
in freely-behaving rats. EMG activity is directly correlated with spinal excitability. Changes in spinal excitability 
are associated with reductions in thermal and mechanical threshold and central sensitisation26.
At 14 and 28 days following model induction there was a significant reduction in the threshold for 
mechanically-evoked EMG responses in MIA-treated rats, compared to saline controls (p = 0.0002 and p = 0.0071 
respectively; Fig. 4A,B). At day 14 in MIA-treated there was no significant difference in the overall magnitude 
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of EMG responses (EMG responses to all hairs) in MIA-treated rats, compared to saline rats (p = 0.9; Fig. 4C). 
However, by day 28 overall EMG responses in MIA rats were increased in magnitude (p = 0.025; Fig. 4D), com-
pared to saline rats. Post-hoc analysis at Day 28 showed a significant difference in the mean EMG response 
evoked by the supra-threshold hair (p = 0.0025 Fig. 4D) in MIA rats, compared to saline rats. The duration of the 
EMG response was also quantified. No significant interaction was observed between groups at 14 days following 
intra-articular injection of MIA (p = 0.2484; Fig. 3E). At day 28 the EMG response duration was significantly 
longer in MIA-rats, compared to saline-treated rats (p = 0.0312; Fig. 4F). Post-hoc analysis revealed a significantly 
longer duration of supra-threshold evoked EMG responses in the MIA-rats, compared to saline-treated rats at this 
late timepoint (p = 0.003; Fig. 4F).
Effects of intra-RVM lidocaine and DAMGO on EMG responses in the MIA model. Intra-RVM 
microinjection sites are were determined post-mortem and are shown in Supplemental Fig. 2. To understand 
the potential influence of descending control pathways in the MIA model of OA pain, we first investigated the 
Figure 1. Intra-articular inactivation of TRPV1 expressing nociceptors reverses NGF induced pain. Intra-
articular NGF (10 μg/50 μl) produced significant WB asymmetry (A) and reductions in PWTs (B) at 2 hours 
post-injection. Subsequent injection (indicated by the black arrow) of membrane impermeable local anaesthetic 
QX-314 alone (●) did not alter NGF-induced pain behaviour. Concomitant injection of QX-314 (1 mg/50 μl) 
with capsaicin (1 μg per μl) (■)significantly reversed WB asymmetry up to 2 hours post-injection (A), but 
had no effect on PWTs (B). ● = QX-314, ■ = QX314 + capsaicin, Δ = capsaicin, ▲ = lidocaine, ○ = vehicle. 
Changes in PWT or WB following NGF injection were performed using a 2-way ANOVA (treatment x 
time) with Dunnett’s multiple comparison test comparing WB and PWT to the measurement. ◆◆◆◆ < 0.0001 
(time 0 vs 2hrs post NGF). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Dunnett’s; 2hrs postNGF vs 
pharmacological intervention)). All data are presented as mean ± SEM.
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Figure 2. Inactivation of TRPV1 expressing nociceptors reverses MIA induced alterations in weight-bearing 
up to Day 14. Intra-articular injection of MIA significantly altered WB 7 (A), 14 (C) and 28 (E) days following 
administration (Dunnett’s; ◆◆◆◆p < 0.0001). At Days 7 (B) and 14 (C) co-administration of QX-314 and 
capsaicin reversed MIA induced alterations in WB asymmetry at Day 7 and 14 but not at Day 28 (F), compared 
pre-injection values. None of the other drugs significantly altered WB asymmetry at Day 7 or 14. However 
at Day 28, capsaicin significantly enhanced WB asymmetry compared to pre-drug, baseline values. ● = QX-
314, ■ = QX314, Δ + capsaicin, = capsaicin, ○ = vehicle. Effects of interventions on WB asymmetry were 
performed using a two-way repeated measures ANOVA with Dunnett’s post-hoc test. *p < 0.05, ***p < 0.001, 
****p < 0.0001 (* QX-314 + capsaicin vs respective baseline value). #p < 0.05, ##p < 0.01, ####p < 0.0001  
(# capsaicin alone vs respective baseline value). All data are presented as mean ± SEM.
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effect of an intra-RVM injection of lidocaine on EMG responses in MIA rats. The RVM contains projections of 
at least two populations of neurons that are able to inhibit or facilitate pain responses at the spinal cord level. 
Intra-RVM lidocaine treatment had no significant effect on any parameter of the EMG responses in MIA-treated 
rats compared to saline controls (see Supplemental Fig. 3). Given the generalised effects of lidocaine on this mixed 
population of neurones in the RVM27, the effect of a more specific intervention using a pharmacological tool 
that activates endogenous pain control systems was studied. The effects of injection of the mu-opioid receptor 
(MOR) agonist DAMGO into the RVM of MIA- and saline-treated rats on EMG thresholds and the magnitude 
of responses were compared to the effects of intra-RVM injection of saline in separate groups of rats. At day 14 
in MIA rats, intra-RVM DAMGO (3 ng) did not alter the threshold of mechanically-evoked EMG responses 
(Fig. 4A), but 30 ng DAMGO significantly increased thresholds compared to MIA rats which received intra-RVM 
saline as a control (p < 0.0001) and MIA rats that received the low dose of intra-RVM DAMGO (3 ng)(p < 0.0001; 
Fig. 4A). In the Day 28 MIA group of rats, both 3 ng and 30 mg intra-RVM DAMGO significantly increased EMG 
thresholds in MIA rats, compared to intra-RVM-saline in MIA rats (p < 0.0001 in both comparisons Fig. 4B). 
These data show altered sensitivity of the RVM to activation of opioidergic signalling at later time points in the 
MIA model. Intra-RVM injection sites were confirmed at the end of each recording session (Supplementary 
Figure 1).
To further analyse the change in opioid sensitivity we performed post-hoc analyses of responses to threshold 
(Fig. 4C) and suprathreshold (Fig. 4D) mechanical stimuli in MIA and saline rats at Day 14 and 28 in separate 
groups of rats.
Threshold Responses. At day 14 intra-RVM DAMGO (3 ng) had the same effect in both saline and MIA treated 
rats. However at Day 28 3 ng DAMGO caused significantly greater analgesia in MIA treated rats than in saline 
controls (p < 0.05). Administration of 30 ng intra-RVM DAMGO to MIA treated rats at both day 14 (p < 0.0001) 
and day 28 (p < 0.01) produced significantly more analgesia than when the same concentration was applied to 
saline controls. In MIA treated rats low dose intra-RVM DAMGO (3 ng) had a significantly greater analgesic 
effect at day 28 compared to day 14 (p < 0.05).
Suprathreshold Responses. Responses to these higher intensity stimuli were less complex than to threshold stim-
uli. Low dose DAMGO (3 ng) had the same effect in MIA and saline treated rats at Day 14 but had a significantly 
greater effect in MIA treated rats at Day 28. DAMGO (30 ng) had a greater effect at Day 14 than 3 ng DAMGO 
(p < 0.01). Low dose of DAMGO was more efficacious in producing analgesia at Day 28 than it was at Day 14 
(p < 0.05).
These data illustrate that the sensitivity μ-opioid receptor activated endogenous pain control systems in the 
RVM are increased at later time points in the MIA model of OA pain, indicative of alterations in endogenous 
opioidergic signalling.
Discussion
Here we provide new evidence for a differing contribution of peripheral inputs to the early versus late stages of 
MIA-induced OA pain and for an alteration in opioid mediated top-down control of spinal excitability and cen-
tral sensitization in the late stage of the model. We have demonstrated that behavioural responses following the 
induction of acute inflammatory joint pain induced by NGF or the earlier stages of longer lasting OA-like joint 
pain induced by MIA were significantly attenuated by transient inactivation of TRPV1 expressing nociceptors in 
the affected knee using QX-314 plus capsaicin. The ability of QX-314 plus capsaicin to attenuate pain behavioural 
responses at early but not late stages of the MIA model suggests either a significant phenotypic switch in the 
peripheral input driving pain (i.e. within nociceptors), or an increased central contribution to the maintenance of 
this pain. Appreciating the presence and timecourse of this switch is important in targeting the pharmacological 
management of OA pain to the appropriate target (i.e. peripheral inflammation versus altered CNS function).
Intra-articular injection of NGF resulted is an acute WB asymmetry and lowered PWTs consistent with 
NGF-induced sensitisation of TRPV1 channels via activation of TrkA receptors, and facilitated responses of these 
nociceptors to capsaicin28. Acute intra-articular injection of QX-314 plus capsaicin had a selective inhibitory 
effect on WB asymmetry, but not lowered PWTs. In the absence of the TRPV1 ligand capsaicin, QX-314 did not 
alter WB asymmetry, consistent with other studies using this pharmacological intervention to target TRPV1 
positive sensory nerves29. NGF-induced lowering of hindpaw withdrawal thresholds (distal allodynia), thought to 
arise from alterations in the central processing of nociceptive inputs, was unaffected by sensory specific blockade 
of joint nociceptors by QX-314 plus capsaicin. NGF-induced distal allodynia persists up to 3 days post-injection30 
Days Post-MIA
QX314 vs 
QX314 + capsaicin
Capsaicin vs 
QX314 + capsaicin
Lidocaine vs 
QX314 + capsaicin
Vehicle vs 
QX314 + capsaicin
7 — **** ** *
14 * *** **** **
28 — — — —
Table 1. The effect of intra-articular pharmacological treatments at days 7, 14 and 28 on WB asymmetry in 
MIA pre-treated rats. Comparisons between QX-314 + capsaicin treated rats have been made with QX-314, 
capsaicin, lidocaine and vehicle treated rats. Comparisons were made with a repeated measure 2-way ANVOA 
with Sidak’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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and the continued presence of distal allodynia following the blockade of TRPV1 expressing sensory input from 
the joint at 2 hours following NGF injection, suggests that relatively short term activation of sensory nerves by 
NGF in the joint is sufficient to induce long lasting central changes31 that are not reversed by the removal of 
peripheral input.
Figure 3. QX-314 + capsaicin is unable to effect MIA induced distal allodynia. Intra-articular injection of MIA 
significantly lowered PWTs 7 (A), 14 (C) and 28 (E) days following administration (Dunnett’s; ◆◆◆◆p < 0.0001). 
Subsequent pharmacological treatments (intra-articular injection) were without effect at any of the post-
MIA timepoints. ● = QX-314, ■ = QX314, Δ + capsaicin, = capsaicin, ○ = vehicle All data are presented as 
mean ± SEM.
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In the MIA model of joint pain, rats exhibited significant pain behaviour (WB asymmetry and lowered PWTs) 
at the earlier timepoints studied (7 and 14 days post-injection). At these two timepoints, intra-articular injec-
tion of QX-314 plus capsaicin significantly inhibited WB asymmetry, consistent with the known peripheral joint 
inflammation, increased spontaneous firing of nociceptive afferents at 14 days in the MIA model32 and that local 
blockade of TRPV1 in the joint reversed established MIA-induced pain behaviour33. Consistent with our findings 
in the acute NGF model, QX314 plus capsaicin treatment had no effect on lowered PWTs in MIA rats at day 7 or 
day 14. Overall these data support a major contribution of TRPV1 positive sensory joint fibres to the WB asym-
metry, but not lowered PWTs, at the early stages of the MIA model of OA pain. Recently it has been shown that 
chemogenetic inhibition of NaV 1.8 expressing neurons blocks hyperalgesia in early experimental knee osteo-
arthritis34 which supports our data that TRPV1 expressing nociceptors (a subset of Nav 1.8 expressing C-fibres) 
underpin the development of joint pain.
Figure 4. MIA leads to a increased sensitivity of endogenous opioid signaling within the RVM. EMG 
characterization of the nociceptive withdrawal reflexes in rats. Thresholds for mechanically evoked EMGs 
were significantly reduced in MIA-treated rats compared to saline rats at 14 (A) and 28 days (B) following 
intra-articular injection of MIA. Intra-RVM administration of 3 ng DAMGO did not alter MIA induced 
reductions in EMG threshold at Day 14 (A), but did reverse this reduction at Day 28 in MIA rats (B). Intra-
RVM administration of DAMGO (3 ng) significantly inhibited EMG response magnitude to threshold vFh 
stimulation in saline (white bars) and MIA (black bars) treated rats at Day 14 compared to baseline (pre-drug) 
values. Low dose DAMGO (3 ng) was reduced EMG responses to threshold stimuli (C) in MIA treated rats 
at both Day 28 compared to saline treated controls but high dose DAMGO (30 ng) reduced responses at both 
Day14 and 28. A similar but not identical pattern was seen following DAMGO to responses to suprathreshold 
stimuli (D). Threshold determinations were compared using a one-way ANOVA with Bonferroni post-test. 
EMG magnitude and duration were compared between groups using a two-way repeated measures ANOVA 
with Sidak post-hoc test **p < 0.01, ***p < 0.001, ****p < 0.0001. Day 14: MIA (n = 27 rats); Saline (n = 29 
rats). Day 28: MIA (n = 50 rats); Saline (n = 38 rats). All data are presented as mean ± SEM.
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The lack of efficacy of intra-articular injection of lidocaine in reversing either NGF or MIA mediated WB 
asymmetry is surprising. The concentration of lidocaine that was used in the studies is the same that has been 
used previously35. We consider a period of at least 30 mins is necessary after the intra-articualr injection of lido-
caine (under general anaesthesia) is necessary before further behavioural assessments can be made to mitigate 
against anaesthetic impacting upon behaviour. Previous studies which have shown a positive effect of lidocaine 
upon pain behaviour in this context and the lack of efficacy in our studies of lidocaine may well reflect the fact 
that compared to these studies the volume used was smaller35. Similarly intra-RVM lidocaine failed to alter 
descending control in our study. Although the concentration and volume of lidocaine microinjected in our study 
has been used successfully by others36 it is at the lower end of range used in other studies37 and this may explain 
the lack of efficacy in our hands.
The data demonstrate an effect of QX-314 + capsaicin upon WB but not on VF evoked withdrawal thresholds. 
This would indicate that the selective inactivation of TRPV1 + ve C-fibres only effects MIA induced primary 
hyperalgesia, and has no effect upon the distal allodynia observed by reduced mechanical withdrawal thresholds 
evoked by stimulating the ipsilateral plantar footpad. C-fibres therefore drive weight bearing asymmetry but play 
little to no role in the maintenance of central sensitisation that are thought to underpin allodynia.
In stark contrast to day 7 and 14, intra-articular injection of QX-314 plus capsaicin did not alter WB asymme-
try at 28 days in the MIA model. These data suggest that at this timepoint factors other than TRPV1 expressing 
sensory nerves play a greater contribution to this pain phenotype. Day 28 represents a timepoint at which all 
behavioural changes associated with experimental OA have become fully developed38. The lack of efficacy of 
QX-314 + capsaicin may represent the recruitment of additional/different sensory nerves, or a greater contri-
bution of spinal/supra-spinal mechanisms to WB asymmetry. Previous work from our group has demonstrated 
markers of central sensitization indicative of the transition from acute to chronic pain mechanisms at this time-
point in the MIA model. Specifically, ipsilateral spinal expression of GFAP immunofluorescence is significantly 
elevated in this model at 28 days20, which is linked to hyperalgesia in other models of chronic pain. Previously 
MIA has been shown to result in increased afferent drive that is refractory to the anti-inflammatory actions 
diclofenac or the TRPV1 antagonist HC03003139. This work concluded that afferent drive is essential at 14 days 
post MIA for pain but that TRPV1 did not play a role. Our data add to this by illustrating that afferent drive from 
TRPV1 expressing neurons is essential in the early stages of MIA induced pain, including day14, these are not 
essential in later stages and that whilst the TRPV1 receptor may not be essential in MIA induced WB and PWT 
the neurons they are expressed on are.
It is increasingly recognised that EMG responses are sensitive to disease related alterations in CNS process-
ing23,40 and have great utility for the assay of central sensitisation associated with chronic pain in both animals 
and humans. At 14 and 28 days in the MIA model, rats exhibited reduced reflex thresholds, and at day 28 rats had 
significantly enhanced reflex magnitude. These findings are consistent with a previous animal study of OA23 and 
clinical studies in OA patients4 reporting the presence of central sensitization using EMG as an assay of excit-
ability. EMG reflex responses are sensitive to the inhibitory effects of analgesics which act either directly in the 
spinal cord, or within supraspinal centres that innervate the spinal cord41,42. The RVM is the major source of both 
descending inhibitory and facilitatory influences over DH excitability43. RVM neurophysiology is driven by three 
types of neurone: ON cells which promote chronic pain states and are the only RVM cell type to be directly inhib-
ited by MOR agonists44; OFF cells which decrease their basal activity just before a noxious stimulus; NEUTRAL 
cells show no consistent change in their firing patterns to noxious stimulation. Only ON cells express MOR and 
these receptors suppress the excitability and therefore produce a direct inhibition of descending facilitation [39]. 
However ON and OFF cells are reciprocally connected and inactivation of ON cells will also increase activity in 
OFF cells therefore amplifying DAMGO mediated descending inhibition of DH excitability. In the present study 
low dose DAMGO (3 ng) was able to inhibit spinal excitability in both MIA and saline treated rats in response to 
threshold, but not suprathreshold stimuli. This effect of DAMGO in saline treated rats is unsurprising as the drug 
will have inhibited low level basal descending facilitation and enhanced descending inhibition. Thus the low dose 
of DAMGO can provide enough descending inhibitory drive to overcome the increased excitatory input from 
the MIA effected knee combined with the larger vFh evoked noxious input emanating from the foot. Our major 
finding was that a lower dose of DAMGO had significant inhibitory effects on EMG thresholds and magnitude 
of evoked EMG responses at 28 days in the MIA rats, but not in MIA rats at the earlier timepoints studied. The 
fact that the higher dose of DAMGO (30 ng) significantly inhibited EMG responses in both groups at both times 
whereas the lower dose was most efficacious in MIA rats at Day 28 indicates increased RVM contributions to 
MIA induced pain at the later timepoint and/or increased opioid sensitivity in late stage OA pain. These data 
extend previous indirect evidence for a contribution of supraspinal sites to MIA-induced pain provided by studies 
of the effect of transection of the spinal cord at a thoracic level on pain behaviour23 and that blockade of spinal 
cord 5-HT3 receptors reversed MIA-induced hypersensitivity of spinal dorsal horn neurones24. There may appear 
to be an incongruity between the DAMGO and QX-314 + capsacin data in as much as vFh evoked activity was 
significantly effected by the former by unaffected by the latter. This difference is completely logical when it is 
considered that QX-314 + capsacin only impacted upon sensory neurones that innervated the joint and a limited 
somatotopic region within the DH, whereas RVM administered DAMGO will have decreased DH facilitation 
and increased descending inhibition throughout the entire DH as the RVM has no somatotypic map and RVM 
neurons are known to respond to stimulation across the body.
Our demonstration of a significant change in the opioidergic system sensitivity in the RVM in this model of 
OA pain has considerable significance, both in terms of understanding the neurophysiological substrates driving 
OA pain and the importance of targeting central mechanisms of pain for treatment. OA patients exhibit altera-
tions in supraspinal responses to pain as evidenced by increased activity within the cingulate cortex, thalamus and 
amygdala45. In addition, atrophy of the thalamic46 and cortical gray matter47 that can be reversed by arthroplasty. 
Although, changes in these centres do not directly modulate spinal pain processing they will alter activity within 
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brain centres that do impact upon DH excitability48. Altered diffuse noxious inhibitory control49 (indicating alter-
ations in descending inhibition) and increased activation of the periaqueductal gray50 (a structure that mediates 
its effects on DH excitability indirectly via the RVM) have both been demonstrated in OA patients. The extent 
to which opioidergic systems in the brain are altered in OA patients has yet to be reported. The contribution of a 
supraspinal drive of central sensitization, mediated by the opioidergic system, in established OA pain may reflect 
a functional up-regulation of opioid receptors in the RVM and/or a result of a loss of endogenous mu opioid 
ligand, but this needs experimental confirmation.
In conclusion we have shown that there are specific periods during the development of pain in a model of OA 
in which peripheral input by TRPV1 positive nociceptors innervating the affected joint are a pre-requisite for pain 
on loading of the joint. At later timepoints TRPV1 positive nociceptors are involved to a much lesser extent, but 
neuromodulatory influences from the RVM appear to play a greater role in mediating the increased excitability 
of the DH associated with this model of OA pain. This time-dependent role of the peripheral and central nervous 
system in the development and maintenance respectively of chronic pain states is in agreement with that seen in 
other experimental pain states37. Further investigation is required to elucidate how afferent sensory input leads to 
changes in brainstem pain modulation.
Materials and Methods
Animals. Male Sprague-Dawley rats (180–200 g; Charles River, UK) were used and kept on a 12 h dark/
light cycle, group housed with free access to food and water. All procedures were performed in accordance with 
and specifically licenced under the Animals (Scientific Procedures) Act 1986 following ethical review by The 
University of Nottingham Animal Welfare Ethical Review Body and the UK Home Office. All studies took place 
in accordance with the ARRIVE guidelines. At the end of experiments, rats were killed by overdose of anaesthetic 
followed by cervical dislocation.
Model induction and behavioural testing. Rats were anaesthetised with isoflurane (3% in 99% O2) 
and received a single injection through the infra-patellar ligament of the left knee, of one of the following: 1) 
recombinant rat beta-nerve growth factor [NGF; 10 ug/50 ul; R&D Systems, dose based on30] to model acute joint 
pain, or 2) mono-sodium iodoacetate (MIA; 1 mg/50 µl; Sigma U.K.)33 to model chronic joint pain. Pain behav-
iour was assessed as changes in hindlimb weight-bearing (WB) and changes in mechanical hindpaw withdrawal 
thresholds (PWT) as previously described21 by an experimenter blinded to all treatments. Baseline behavioural 
measurements were taken prior to intra-articular injections. In the NGF model, behaviour was tested pre and 2 
hrs post injection. Following intra-articular injection of MIA, pain behaviour was assessed at day 7, 14, 21 and 28.
Intra-articular drug treatments. Following single injection of NGF or MIA, rats recieved a second 
pharmacologcial intervention at the timepoints as follows: NGF-treated rats at 2 hours post model induc-
tion; MIA-treated rats at 7, 14 or 28 days post model induction. The treatment was one of the following as 
an intra-articular injection in the ipsilateral knee under isoflurane anaesthiesia: lidocaine (1 mg/50 ul; Sigma 
U.K.); QX-314 (N-Ethyllidocaine bromide, 1 mg/50 ul; AbCam); capsaicin (1 ug per ul; Sigma U.K.); QX-314 
(1 mg/50 ul) with capsaicin (1 ug per ul); or vehicle (5% EtOH, 5% tween-20, 90% saline 0.9%) (see Fig. 1). Effects 
of treatments on WB asymmetry and PWTs were assessed at 30, 60, 90, 120, and 180 mins post treatment. The 
local anaesthetic QX314 is membrane impermable, however, co-administration with a low dose of the TRPV1 
ligand capsaicin selectively inactivates the TRPV1 positive subset of sensory neurones29.
EMG recordings and RVM Microinjections. EMG responses and the influence of modulating the output 
from the RVM on these responses was characterised at different stages of the model of OA pain. These studies 
were performed in anaesthetised rats as this permits responses to a range of sub- and suprathreshold stimuli to 
be assessed. Additionally this permits more accurate microinjection of pharmacological tools and has a signfi-
cantly reduced burden of suffering on the animals compared to freely-behaving studies where animals have to 
be fitted with guide cannlulae for a number of days prior to testing. EMG recordings of this type have been used 
to assess central changes in pain processing previously25,41. Rats were anaesthetised with isoflurane (3% in 99% 
O2) and a tracheotomy performed. Rats were artificially ventilated (Harvard Apparatus, UK) via an endotracheal 
cannula. Body temperature was maintained at 37 °C using a homeothermic heated blanket (Harvard Apparatus). 
Rats were mounted on a stereotaxic frame and craniotomies performed over the RVM (anterior-posterior [A-P] 
−11.0 mm, medial-lateral [M-L] 0.0 mm, dorsal-ventral [D-V] −10.5 mm). A custom-built bipolar concentric 
EMG electrode was inserted into the belly of the biceps femoris muscle ipsilateral to the MIA/saline injection. The 
electrode was connected to a NeuroLog head-stage (module NL100AK; Digitimer, Welwyn Garden City, UK), 
signals amplified x2000 (module NL104A), band-pass filtered between 10–1000 Hz (module NL125) before being 
sampled at 2 kHz using Spike2 V.7 software via a micro1401 data acquisition unit (CED, Cambridge, UK) as pre-
viously described41. Isoflurane concentration was reduced stepwise to a final concentration of between 1.0–1.3%, 
which was determined as being the highest concentration that permitted reproducible pedal reflex responses. 
Spinally mediated nociceptive paw withdrawal reflexes were evoked by the application of von Frey hairs to the 
plantar surface of the ipsilateral hindpaw. Mechanical threshold was defined as the minimum mechanical force 
in grams that evoked an increased EMG response at least 10% above basal activity. Once the threshold mechan-
ical force was determined, von Frey hairs were presented in ascending order of bending force, with two below 
threshold, one at threshold and one suprathreshold. The magnitude of EMG responses to subthreshold, threshold 
and supra-threshold stimuli was determined. Each hair was presented 3 times, and 3 evoked baseline responses 
were measured at 10 minute intervals. EMG recording and pharmacological manipulation of the RVM was per-
formed as previously described51. RVM microinjections consisted of administering 200 nl of [D-Ala2, N-MePhe4, 
Gly-ol]-enkephalin (DAMGO (Tocris; UK): 3 ng or 30 ng per microinjection) or lidocaine (10 ng, to inactivate 
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neuronal excitability in all cells in the entire NRM) slowly over 5 mins into the RVM, specifically the nucleus 
raphe magnus. more information see Supplementary Information.
Following both behavioural and EMG studies animals were humanely killed and knees were harvested for his-
tological examination. Animals in the MIA group that did not have verified pathological changes in the injected 
knee indicative of OA-like processes were removed from all data analyses.
Macroscopic confirmation of osteoarthritis. Rats were overdosed with sodium pentobarbital (1 ml, 
intra-periotoneal) and transcardially perfused with saline (0.9%) until exsanguinate ran clear. Infusate Perfusate 
was then switched to 4% paraformaldehyde (PFA; Sigma, U.K) made up in phosphate buffered saline (PBS). 
Whole knees (both ipsilateral and contralateral) were dissected and disarticulated and processed in accordance 
with procedures publihsed previously18. Macroscopic scoring of the chondral surfaces was used to confirm the 
presence of MIA-induced lesions to corroborate behavioural and electrophysiological findings. Macroscopic 
lesions were graded as follows: 0 = normal appearance; 1 = slight yellowish discoloration of the chondral surface; 
2 = little cartilage erosions in load-bearing areas; 3 = large erosions extending down to the subchondral bone; 
and 4 = large erosions with large areas of subchondral bone exposure [scoring system as used in52. Each of the 
chondral surfaces, medial and lateral femoral condyles, medial and lateral tibial plateaus and the femoral groove, 
was graded separately by 2 observers. Scores for each of the 5 regions were combined (maximum possible score 
of 20) and the mean determined for each group.
Group Sizes and Statistical Analysis. Allocation and blinding: prior to any intervention baseline behav-
ioural measures, WB and PWT, were taken and animals assigned to either MIA/NGF or saline groups so that 
each group had equivalent means. Within these two groups, rats were assigned into groups for further pharma-
cological interventions on the basis of their WB and PWT values post the intial intervention so that mean values 
of these parameters within each group (MIA/NGF or saline) were comparable. Drugs used in this study were 
prepared by the authors and then anonymised and encoded. The instructions for which coded drug solution was 
given to each coded animal was then provided to the experimenter. Allocation and blinding was performed by a 
third party researcher who had no part in the study and is not an author on this publication.
Group sizes for studies were determined using Power Calcualtions using data obtained in our laboratories 
with the same model of OA (behavioural studies) or using the EMG recording to assess the impact of supraspinal 
pharmacological manipulations. The minimum group size required for studies with a systemic pharmacological 
intervention on pain behaviour (mean difference between two groups (drug versus vehicle) was 48.98 (SD 25.05)) 
was 4 rats per group to detect the difference between intervention and vehicle with 90% power and less than 
5% type I error. In these studies experimentors were blind to both intitial treatment (MIA or saline) as well as 
subsequent intra-articular pharmacological challenge. For EMG recordings the minimum group size for studies 
comparing reflex magnitude after a supraspinal pharmacological intervention in MIA and saline treated rats 
(mean difference between groups (baseline versus post-drug) was 49 (SD 36)) with 90% power and less than 5% 
type I error was 6.
Changes in PWT or WB following MIA or NGF injection were performed using a one-way ANOVA with 
Dunnett’s multiple comparison test comparing WB and PWT to the baseline (0) measurement. For comparisons 
between treatment groups after the second intra-articular drug administration (in either the NGF or MIA stud-
ies) a 2-way ANOVA (treament x time) was performed with mean responses of each treatment over the entire 180 
post-drug period compared between groups with a Dunnett’s multiple comparisons test. Analyses were carried 
out using Prism 6.0 software (Graphpad, La Jolla, USA). Raw EMG data was extracted using custom-written 
scripts in MATLAB (R2012a; MathWorks, Natick, MA, USA). Extracted data were imported into Prism and the 
magnitude and duration of baseline evoked EMG responses was compared between MIA and saline groups at dif-
ferent timepoints. EMG thresholds were compared using a one-way ANOVA with Tukey’s multiple comparison 
post-test). The effect of each pharmacological intervention on the magnitude of the EMG response was expressed 
as a percentage of its pre-drug baseline response. Normalised post-drug responses and macroscopic knee scores 
were compared directly between treatments, interventions and timepoints using two-way ANOVA with Sidak 
post-tests.
Data Availability Statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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